Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19 DOI Creative Commons
Ping Xu, Lijun Zhang,

Qingguo Wu

et al.

BMC Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(1)

Published: Dec. 18, 2024

Language: Английский

Population Pharmacokinetics and Dosing Regimen Analysis of Nirmatrelvir in Chinese Patients with COVID-19 Infection DOI Creative Commons

Runcong Zhang,

Jing Fan,

Han Lü

et al.

Drug Design Development and Therapy, Journal Year: 2024, Volume and Issue: Volume 18, P. 5517 - 5527

Published: Dec. 1, 2024

Nirmatrelvir/ritonavir (N/R) is the first drug to receive emergency authorization for treatment of COVID-19 infection. We aimed develop a population pharmacokinetic (PopPK) model evaluate effects potential covariates and explore dosing regimen.

Language: Английский

Citations

0
Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19 DOI Creative Commons
Ping Xu, Lijun Zhang,

Qingguo Wu

et al.

BMC Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(1)

Published: Dec. 18, 2024

Language: Английский

Citations

0